PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Company ReportsCSL Behring
CSL Behring
CSL Behring is a biopharmaceutical company, manufacturing plasma-derived, and recombination therapeutic products. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies (PIDD); hereditary angioedema; inherited respiratory disease; and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment, and to prevent hemolytic diseases in newborns.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
AfstylaLonoctocog alfa, Antihemophilic factor2017-01-04
Albuminar, albuminar, albuminar, albuminarAlbumin human2000-03-17
—
AlburxAlbumin human1976-07-23
—
BerinertConestat alfa2009-10-09
Carimune, carimune nf, panglobulin, sandoglobulinHuman immunoglobulin g2000-07-27
Gammar i.v.,gammar-pHuman immunoglobulin g2000-03-17
HaegardaConestat alfa2017-06-22
HizentraHuman immunoglobulin g2011-04-14
Humate-pAntihemophilic factor, Von willebrand factor human2000-04-11
1
2
>
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Lonoctocog alfa
1
2
3
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use